US EditionPublished • loading... • Updated
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
NFI reports record Q4 and full-year 2025 results, with backlog growing to $13 billion and adjusted EBITDA surging 78.7% year-over-year.
- Financial results released Tuesday, March 10, by Petco show net income of $9.1 million and a 21.3% increase in adjusted EBITDA to $408.2 million, despite a 2.5% decline in net sales to $6.0 billion.
- Rebuilding the foundation of its economic model, Petco stated that during 2025, it exceeded profitability goals and strengthened its leadership team.
- Simmons highlighted that Petco reduced its leverage ratio to 3.0x at the end of 2025, down from 4.2x at the start of the year, driven by improved profitability and strategic debt management.
- Petco completed a debt refinancing that extended maturities to 2031 and increased balance sheet flexibility, according to management.
- Management projects fiscal 2026 revenue between $3.9 billion and $4.2 billion, with EBITDA guidance from $370 million to $410 million, assuming tariff levels stay as of March 11, 2026.
Insights by Ground AI
68 Articles
68 Articles
The Billings Gazette+11 Reposted by 11 other sources
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025.
·Billings, United States
Read Full Article
Coverage Details
Total News Sources68
Leaning Left14Leaning Right3Center21Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 37%
C 55%
Factuality
To view factuality data please Upgrade to Premium
